These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Huntington Study Group Neurology; 2003 Dec; 61(11):1551-6. PubMed ID: 14663041 [TBL] [Abstract][Full Text] [Related]
3. Riluzole in Huntington's disease (HD): an open label study with one year follow up. Seppi K; Mueller J; Bodner T; Brandauer E; Benke T; Weirich-Schwaiger H; Poewe W; Wenning GK J Neurol; 2001 Oct; 248(10):866-9. PubMed ID: 11697523 [TBL] [Abstract][Full Text] [Related]
4. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC; Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031 [TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Jankovic J; Hunter C Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422 [TBL] [Abstract][Full Text] [Related]
6. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Abdallah CG; Coplan JD; Jackowski A; Sato JR; Mao X; Shungu DC; Mathew SJ Neurosci Lett; 2012 Nov; 530(1):103-7. PubMed ID: 23043888 [TBL] [Abstract][Full Text] [Related]
7. A systematic review of the treatment studies in Huntington's disease since 1990. Bonelli RM; Hofmann P Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085 [TBL] [Abstract][Full Text] [Related]
8. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Jenkins BG; Koroshetz WJ; Beal MF; Rosen BR Neurology; 1993 Dec; 43(12):2689-95. PubMed ID: 8255479 [TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146 [TBL] [Abstract][Full Text] [Related]
11. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329 [TBL] [Abstract][Full Text] [Related]
12. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Armstrong MJ; Miyasaki JM; Neurology; 2012 Aug; 79(6):597-603. PubMed ID: 22815556 [TBL] [Abstract][Full Text] [Related]
13. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Grant P; Lougee L; Hirschtritt M; Swedo SE J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):761-7. PubMed ID: 18315448 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of riluzole in Huntington's disease. Squitieri F; Ciammola A; Colonnese C; Ciarmiello A Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):221-2. PubMed ID: 17987289 [No Abstract] [Full Text] [Related]
16. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461 [TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836 [TBL] [Abstract][Full Text] [Related]
18. Open-label trial of riluzole in generalized anxiety disorder. Mathew SJ; Amiel JM; Coplan JD; Fitterling HA; Sackeim HA; Gorman JM Am J Psychiatry; 2005 Dec; 162(12):2379-81. PubMed ID: 16330605 [TBL] [Abstract][Full Text] [Related]
19. Huntington's disease: present treatments and future therapeutic modalities. Bonelli RM; Wenning GK; Kapfhammer HP Int Clin Psychopharmacol; 2004 Mar; 19(2):51-62. PubMed ID: 15076012 [TBL] [Abstract][Full Text] [Related]